| Source: HalifaxProj (inhibit) CGL-Driver Genes |
| Type: Antiapoptotic Oncogene |
| The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID. Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells. |
| 425- | CUR, | Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 426- | CUR, | Use of cancer chemopreventive phytochemicals as antineoplastic agents |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | CAL51 |
| 447- | CUR, | OXA, | Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway |
| - | vitro+vivo, | CRC, | HCT116 |
| 456- | CUR, | Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells |
| - | vitro+vivo, | GC, | SGC-7901 |
| 453- | CUR, | Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 448- | CUR, | Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation |
| - | in-vitro, | CRC, | HT-29 |
| 444- | CUR, | Cisplatin, | LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells |
| - | vitro+vivo, | CRC, | HCT8 |
| 441- | CUR, | Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p |
| - | in-vitro, | CRC, | HCT116 |
| 136- | CUR, | docx, | Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 137- | CUR, | Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling |
| - | in-vitro, | Pca, | DU145 |
| 141- | CUR, | Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer |
| - | in-vivo, | Pca, | PC3 |
| 118- | CUR, | Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 15- | CUR, | UA, | Effects of curcumin and ursolic acid in prostate cancer: A systematic review |
| - | Review, | Pca, | NA |
| 12- | CUR, | Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells |
| - | in-vitro, | MB, | DAOY |
| 9- | CUR, | Curcumin Suppresses Malignant Glioma Cells Growth and Induces Apoptosis by Inhibition of SHH/GLI1 Signaling Pathway in Vitro and Vivo |
| - | vitro+vivo, | MG, | U87MG | - | vitro+vivo, | MG, | T98G |
| 170- | CUR, | Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis |
| - | vitro+vivo, | Pca, | PC3 |
| 6236- | CUSP9, | EP, | Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro |
| - | in-vitro, | GBM, | U251 |
| 1871- | DAP, | Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth |
| - | in-vitro, | AML, | U937 | - | in-vivo, | AML, | NA |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 4455- | DFE, | Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | 3T3 |
| 6289- | DL, | D-Limonene modulates inflammation, oxidative stress and Ras-ERK pathway to inhibit murine skin tumorigenesis |
| - | in-vivo, | Var, | NA |
| 6269- | DL, | Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells |
| - | in-vitro, | CRC, | LS174T |
| 6273- | DL, | D-Limonene Exhibits Antiproliferative Activity Against Human Colorectal Adenocarcinoma (Caco-2) Cells via Regulation of Inflammatory and Apoptotic Pathways |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Colon, | HCT116 |
| 6288- | DL, | From Citrus to Clinic: Limonene’s Journey Through Preclinical Research, Clinical Trials, and Formulation Innovations |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6281- | DL, | Applications of Limonene in Neoplasms and Non-Neoplastic Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Diabetic, | NA |
| 6280- | DL, | Biochemical significance of limonene and its metabolites: future prospects for designing and developing highly potent anticancer drugs |
| - | Review, | Var, | NA |
| 6328- | DRE, | Hydroalcoholic extract of Taraxacum officinale induces apoptosis and autophagy in 4T1 breast cancer cells |
| - | in-vitro, | BC, | 4T1 |
| 6343- | DRE, | Dandelion root extract affects ESCC progression via regulating multiple signal pathways |
| - | vitro+vivo, | ESCC, | NA |
| 6350- | DRE, | Tracking Evidences of Dandelion for the Treatment of Cancer: From Chemical Composition, Bioactivity, Signaling Pathways in Cancer Cells to Perspective Study |
| - | Review, | Var, | NA |
| 6318- | DRE, | Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways |
| - | vitro+vivo, | CRC, | HCT116 | - | NA, | Nor, | NCM460 |
| 6354- | DRE, | Taraxacum officinale L. in leukemia and lymphoma: current knowledge and prospects for horticulture |
| - | Review, | AML, | NA |
| 6363- | DRE, | Therapeutic Potential of Dandelion (Taraxacum officinale) Root Extract in Colon Cancer: A Comprehensive Review |
| - | in-vitro, | CRC, | NA |
| 1621- | EA, | The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art |
| - | Review, | Var, | NA |
| 1606- | EA, | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
| - | in-vitro, | Colon, | HCT15 |
| 1613- | EA, | Ellagitannins in Cancer Chemoprevention and Therapy |
| - | Review, | Var, | NA |
| 27- | EA, | Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice |
| - | in-vivo, | PC, | PANC1 |
| 20- | EGCG, | Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer |
| - | in-vivo, | Liver, | NA | - | in-vivo, | Tong, | NA |
| 22- | EGCG, | Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics |
| - | in-vitro, | PC, | CD133+ | - | in-vitro, | PC, | CD44+ | - | in-vitro, | PC, | CD24+ | - | in-vitro, | PC, | ESA+ |
| 23- | EGCG, | (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells |
| - | in-vitro, | Chon, | SW1353 | - | in-vitro, | Chon, | CRL-7891 |
| 668- | EGCG, | The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment |
| - | Review, | BC, | MCF-7 | - | Review, | BC, | MDA-MB-231 |
| 651- | EGCG, | Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications |
| 685- | EGCG, | CUR, | SFN, | RES, | GEN | The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein |
| - | Analysis, | NA, | NA |
| 680- | EGCG, | Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea |
| - | Review, | NA, | NA |
| 3201- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 4682- | EGCG, | Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate |
| - | Review, | Var, | NA |
| 1303- | EGCG, | (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation |
| - | in-vitro, | EC, | NA |
| 1516- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 5225- | EMD, | Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3 |
| - | vitro+vivo, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 5223- | EMD, | Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Nor, | CCD841 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:27 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid